8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)
G.G. Steger, R. Greil, R. Jakesz, A. Lang, B. Mlineritsch, M. Rudas, C. Marth, H. Stoeger, C.F. Singer, M. GnantVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70040-9
File:
PDF, 47 KB
english, 2010